EP1207862A2 - Traitement de l'arthrite - Google Patents

Traitement de l'arthrite

Info

Publication number
EP1207862A2
EP1207862A2 EP00935346A EP00935346A EP1207862A2 EP 1207862 A2 EP1207862 A2 EP 1207862A2 EP 00935346 A EP00935346 A EP 00935346A EP 00935346 A EP00935346 A EP 00935346A EP 1207862 A2 EP1207862 A2 EP 1207862A2
Authority
EP
European Patent Office
Prior art keywords
catechin
arthritis
arthritic
cartilage
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00935346A
Other languages
German (de)
English (en)
Inventor
David Buttle
Clair Adcocks
Peter Collin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Sheffield
Original Assignee
University of Sheffield
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0007321A external-priority patent/GB0007321D0/en
Application filed by University of Sheffield filed Critical University of Sheffield
Publication of EP1207862A2 publication Critical patent/EP1207862A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

  • the invention relates to the use of catechins, or varients thereof, in the treatment of all forms of arthritis.
  • Green tea is a very common drink in the Far East and its beneficial health properties have been recognised for many hundreds of years. Green tea has therefore been the subject of extensive research to identify the active agents responsible for said beneficial health effects. Green tea is a complex mixture of naturally occurring plant extracts. A group of these is variously described as flavanols, catechins or proanthocyanidins. The commonest of these in green tea are: epicatechin (EC), epigallocatechin (EGC), epicatechin gallate (ECG) and epigallocatechin gallate (EGCG), please see Figure 1.
  • Catechins have been reported to alleviate a number of clinical conditions. These include stroke and cerebral haemorrhage (Sato et al, 1989), cardiovascular and liver diseases (Imai & Nakachi, 1995), bacterial infections (Ikigai et al, 1993) and stomach ulcers (Murakami et al, 1992). Catechins have also been shown to inhibit the release of histamine and leukotriene which indicates that catechins may have benefit with regard to the treatment of various allergic disorders (Matsuo et al, 1997).
  • catechins have also been shown to inhibit the lipopolysaccharide (LPS) induced release of tumour necrosis factor ⁇ (TNF ⁇ ) production at the level of both transcription and release from activated macrophages and therefore may have use in the inhibition of inflammation (Yang et al, 1998).
  • LPS lipopolysaccharide
  • TNF ⁇ tumour necrosis factor ⁇
  • Catechins have been shown to regulate cholesterol levels; to have anti-mutagenic properties; to reduce blood pressure; to inhibit the effects of various agents on the liver and can also protect teeth from decay.
  • Clearly catechins have a number of beneficial health effects which are well known in the art.
  • Catechin is a generic name for a group of compounds based on the structure catechin itself, (3',3',4',5,7-flavanpentol), please see Figure 1.
  • catechins are chondroprotective, that is they inhibit the breakdown of cartilage extracellular matrix.
  • EGCG, ECG and EC at a dose of 20 ⁇ M significantly inhibited proteoglycan loss resulting from treatment of bovine cartilage explants with recombinant human interleukin l ⁇ (rhIL- ⁇ ).
  • rhIL- ⁇ recombinant human interleukin l ⁇
  • EGCG produced a dose-response curve for inhibition of proteoglycan loss, with about 50% inhibition being achieved at a concentration of 2 ⁇ M, please see Figure 2.
  • EGCG showed no toxic effects. At 218 ⁇ M EGCG was without effect on lactate production by the explants.
  • EGCG is reported to inhibit TNF ⁇ synthesis (Yang et al, 1998; Suganuma et al, 1996), which may provide the basis for its anti-inflammatory effects.
  • At a concentration of 20 ⁇ M it inhibited bacterial lipopolysaccharide-stimulated TNF ⁇ synthesis from blood samples from two different volunteers by 66% and 30%o using two different commercially available ELISA kits.
  • this cannot provide the mechanism for inhibition of cartilage breakdown as large amounts of exogenous cytokine are added to the cartilage culture in experiments such as those shown in Figure 2. This leads to the conclusion that catechins have two distinct properties that should be beneficial to arthritis sufferers, an anti-inflammatory and a distinct chondroprotective effect.
  • said catechin is selected from: (+)epicatechin, (+)catechin, (-)epicatechin; (-)catechin, (-)epigallocatechin; (-)gallocatechin; (-)epicatechin gallate; (-)catechin gallate; (-)epigallocatechin gallate; (-)gallocatechin gallate; or varients thereof.
  • said catechin is epigallocatechin gallate.
  • said catechin is epicatechin gallate.
  • said medicament is for the treatment of arthritic conditions selected from: osteoarthritis, rheumatoid arthritis; inflammatory arthritis; osteochondritis; acute pyrophosphate arthritis: reactive arthritis; psoriatic arthritis; juvenile arthritis; lupus erythematosus; Sjogren's syndrome; relapsing polychondritis; ankylosing spondylitis; psoriatic arthritis; MSUM (gout); CPDD (pseudogout, chondrocalcinosis); chondrolysis; bursitis.
  • arthritic conditions selected from: osteoarthritis, rheumatoid arthritis; inflammatory arthritis; osteochondritis; acute pyrophosphate arthritis: reactive arthritis; psoriatic arthritis; juvenile arthritis; lupus erythematosus; Sjogren's syndrome; relapsing polychondritis; ankylosing spondylitis; psoriatic arthritis; MSUM (gout); CP
  • said medicament is for the treatment of osteoarthritis.
  • said medicament is for the treatment of rheumatoid arthritis.
  • said medicament is for the use in prophylactic treatment of arthritis.
  • said prophylactic treatment is for animals with a genetic predisposition to arthritis, preferably osteoarthritis.
  • said prophylactic treatment is to protect animals with an increased probability of developing arthritis due to joint damage (eg. cruciate ligament damage). It is well known in the art that individuals which suffer joint damage have an increased incidence of arthritis (Price et al., 1999).
  • a therapeutic composition comprising at least one catechin and at least one anti-arthritic agent or biopolymer.
  • said composition is for use in the manufacture of a medicament for the treatment of arthritis, ideally osteoarthritis.
  • said anti-arthritic agent is hyaluronic acid, or varients thereof.
  • said anti-arthritic agent is glucosamine, or varients thereof, preferably glucosamine sulphate. It is reported that glucosamine is an effective treatment of arthritic conditions (MacCarty, 1994; MacCarty, 1998). Current opinion suggests that glucosamine stimulates the production of glycosaminoglycans, such as hyaluronic acid in joints.
  • Hyaluronic acid is a polymer of N-acetyl glucosamine and glucuronic acid molecules and is well known to have anti-arthritic properties (Balazs, 1968; Gibbs et al, 1968; Balazs & Gibbs.. 1970; Rydell et al, 1970; Weiss et al, 1981 ; Denlinger, 1982; Balazs,1982; Balazs & Denlinger, 1985; Weiss. & Balazs, 1987; Balazs & Denlinger, 1989; McCain et al, 1989; Adams, 1993; Balazs & Denlinger.
  • Hyaluronic acid can vary in molecular mass from 50kDa to 8 x 10 3 kDa and forms highly viscous solutions. Methods to prepare pure samples, which are non-inflammatory, are well known in the art. For example, EP 0239335 & US 4879375 disclose methods to prepare highly pure fractions of hyaluronic acid which purport to be non-inflammatory. Hyaluronic acid is known to have a variety of therapeutic effects.
  • Hyaluronic acid provides visco- supplementation and/or viscolubrication (Balazs & Denlinger, 1993; Peyron, 1993a; Scale et al., 1994; Lussier et al., 1996) to replace fragmented hylauronic acid as a consequence of arthritic disease.
  • said catechin and anti-arthritic agent are administered as a simple admixture.
  • said catechin and anti-arthritic agent are crosslinked, coupled or associated together.
  • Hyaluronic acid has a number of free hydroxyl and carboxyl groups to which catechins may be crosslinked or coupled either directly or via crosslinking agents.
  • hyaluronic acid and a catechin are encapsulated within a liposome preparation as detailed below.
  • said catechin is crosslinked, coupled or associated with hyaluronic acid.
  • a method to crosslink or couple at least one catechin to at least one anti-arthritic agent comprising:
  • said anti-arthritic agent is hyaluronic acid and said catechin is selected from: (+)catechin; (+)epicatechin; (-)catechin; (-)epigallocatechin; (-)gallocatechin; (-)epicatechin gallate; (-)catechin gallate; (-)epigallocatechin gallate; (-)gallocatechin gallate; or varient thereof.
  • a method of treating an arthritic condition comprising administering to an animal a pharmacologically effective amount of the therapeutic composition/medicament according to the invention.
  • said arthritic condition is selected from; osteoarthritis; rheumatoid arthritis; osteochondritis; acute pyrophosphate arthritis; reactive arthritis; psoriatic arthritis; juvenile arthritis; lupus erythematosus: Sj ⁇ gren's syndrome; relapsing polychondritis; ankylosing spondylitis; psoriatic arthritis; MSUM (gout); CPPD (pseudogout, chondrocalcinosis); chondrolysis; bursitis.
  • said arthritic condition is osteoarthritis.
  • said arthritic condition is rheumatoid arthritis.
  • compositions/medicaments can be formulated in a variety of ways to facilitate delivery.
  • liposomal compositions may be usefully employed to deliver said compositions/medicaments.
  • Liposomes are lipid based vesicles which encapsulate a selected therapeutic agent which is then introduced into a patient.
  • the liposome is manufactured either from pure phospholipid or a mixture of phospholipid and phosphoglyceride.
  • liposomes can be manufactured with diameters of less than 200nm, which enables them to be intravenously injected and able to pass through the pulmonary capillary bed.
  • biochemical nature of the liposomes confers permeability across blood vessel membranes to gain access to selected tissues. Liposomes do have a relatively short half-life. So-called STEALTH ® liposomes have been developed which comprise liposomes coated in polyethylene glycol (PEG).
  • the PEG treated liposomes have a significantly increased half-life when administered intravenously to a patient.
  • STEALTH® liposomes show reduced uptake in the reticuloendothelial system and enhanced accumulation in selected tissues.
  • so called immuno-liposomes have been developed which combine lipid based vesicles with an antibody or antibodies, to increase the specificity of the delivery of the therapeutic composition/medicament to a selected cell/tissue.
  • liposomes as a delivery means is described in US 5580575 and US 5542935.
  • compositions/medicaments can be imbided or provided in the form of an oral or nasal spray, an aerosol, suspension, emulsion, and/or eye drop.
  • the medicament may be provided in tablet form.
  • Alternative delivery means include inhalers or nebulisers.
  • the medicament can be delivered by direct injection into a joint. It is envisioned that the compositions/medicaments be delivered intravenously, intramuscularly, subcutaneously or topically. Further still, the medicament may be taken rectally.
  • compositions/medicaments are effective at preventing and/or alleviating arthritic conditions in animals other than humans, for example and not by way or limitation, family pets, livestock, horses.
  • a method to screen for agents with anti-arthritic properties comprises:
  • said inflammatory cytokine is selected from:interleukin-l ⁇ ; interleukin-l ⁇ ; oncostatin M; tumour necrosis factor- ⁇ .
  • said method comprises:
  • vitamin A metabolite is all-/rar ⁇ -retinoic acid.
  • an agent identified by the screening method of the invention is provided.
  • catechins disclosed above can either be isolated from natural plant sources, eg Camellia sinensis, Uncarcia gambir or can be synthesised in the laboratory using methods well known in the art.
  • Table 1 represents the inhibitory effects of catechins on cytokine or vitamin A metabolite-stimulated cartilage breakdown using (i) nasal cartilage explants and (ii) articular cartilage explants;
  • Table 2 represents the inhibitory effects of EGCG and ECG on human osteoarthritic cartilage explants
  • Table 3 represents the inhibitory effects of EGCG and ECG on the degradation of proteoglycan of human rheumatoid knee cartilage
  • Table 4 represents the inhibitory effects of EGCG and ECG on the degradation of proteoglycan of human non-arthritic cartilage
  • Tables 5 and 6 represent the inhibitory effects of EGCG, ECG, EC and EGC on type II collagen degradation in bovine nasal cartilage explants stimulated with rhIL ⁇ ;
  • Table 7 demonstrates lactate production by the explants over the latter part of a 28- day period
  • Table 8 represents the inhibitory effects of EGCG on the synthesis of human TNF ⁇
  • Figure la and lb represents the chemical structures of a selection of catechins and variants thereof;
  • Figure 2 represents the dose-response for EGCG inhibitory activity of TNF ⁇ induced cartilage proteoglycan breakdown
  • Figure 3 represents the macroscopic changes in bovine nasal cartilage explants cultured in the presence or absence of rhIL-l ⁇ , EC and EGC for a 28 day period. Introduction.
  • Cartilage proteoglycan degradation in the bovine system was stimulated with the proinflammatory cytokines interleukinl ⁇ (ILl ⁇ ) or tumour necrosis factor ⁇ (TNF ⁇ ) or with the vitamin A derivative, all-trans retinoic acid (Ret).
  • the degradatory process was initiated in the human cartilage using a combination of interleukinl ⁇ (ILl ⁇ ) and TNF ⁇ .
  • ILl ⁇ interleukinl ⁇
  • TNF ⁇ all-trans retinoic acid
  • Bovine nasal septum and metacarpophalangeal cartilage was prepared as described by Buttle et al, (1992).
  • the nasal septum cartilage was removed using a post-mortem knife and the overlying membrane was discarded.
  • the excised cartilage was wiped with isoprenyl-impregnated Azowipes, placed in a petri dish in the tissue culture hood and washed in sterile phosphate buffered saline (PBS).
  • PBS sterile phosphate buffered saline
  • the cartilage was sliced using a scalpel blade into approximately 2mm x 3mm x 3cm slices, and from these slices discs were cut with the aid of a belt punch. About 200 discs ( ⁇ 3mm diam., 2mm thick) were obtained from each animal.
  • Cartilage explants treated as described above were individually transferred into the wells of a 96-well plate and cultured for up to 9 days (medium change on days 3 and 6 or on day 4) in serum-free DMEM in the presence or absence of recombinant human ILl ⁇ (rhILl ⁇ ), recombinant human ILl ⁇ (rhILl ⁇ ), recombinant human TNF ⁇ (rhTNF ⁇ ) and Ret, either singly or in combination.
  • rhILl ⁇ recombinant human ILl ⁇
  • rhILl ⁇ recombinant human ILl ⁇
  • rhTNF ⁇ recombinant human TNF ⁇
  • Ret Ret
  • sGAGs sulfated glycosaminoglycans
  • Certain catechins were prepared as stock solutions in dimethyl sulfoxide (DMSO) and further diluted in DMSO or DMEM to give the appropriate final concentration in the culture medium and also a
  • sGAGs within the conditioned media and retained in the tissue were either determined by the dimethylmethylene blue assay (Farndale et al., 1986) or by scintillation counting following labelling with SO 4 (Ilic et al, 1995). Data were expressed as the percentage sGAG released from the tissue or as the percentage inhibition of sGAG release. The Mann- Whitney U test for unpaired, non-parametric data was used to determine the statistical significance of the results.
  • Type II collagen breakdown in rhIL-l ⁇ -stimulated bovine nasal cartilage explants
  • bovine nasal cartilage explant cultures were maintained for 28 days, with a twice-weekly medium change, in the presence or absence of rhIL-l ⁇ (4.5nM) and the catechins; EGCG, ECG, EC and EGCG at 20 ⁇ M.
  • type II collagen remaining in the cartilage residues was extracted by digestion with proteinase K (EC 3.4.21.64) at 56°C for 15 hours.
  • the extracts were assayed by- inhibition enzyme-linked immunosorbent assay (ELISA) using a mouse IgG monoclonal antibody to denatured type II collagen, Col2-3/4m as previously described (Hollander et al. 1994).
  • the amount of collagen released at each medium change throughout the culture period was calculated as a percentage of total collagen in each culture well (medium plus tissue residue).
  • Bovine nasal cartilage explants were obtained as described above. The rate of proteoglycan synthesis was assessed by measuring incorporation of 3:> S from 35 SO 4 .
  • Three groups were set up: (a) killed explants (freeze-thawed thrice), (b) explants cultured in serum-free DMEM alone, (c) explants cultured in serum-free DMEM and 2 ⁇ M or 20 ⁇ M EGCG. All three groups were cultured in the presence of 5 ⁇ Ci 33 SO 4 /ml for 18 hours and 3" S incorporation was assessed as previously described by Buttle et al. (1993).
  • Lactate test for assessment of chondrocyte metabolic activity Lactate test for assessment of chondrocyte metabolic activity.
  • a measure of the toxicity of a compound can therefore be made by determining the levels of lactate in the conditioned media by using the lactate oxidase/peroxidase method with a kit from Sigma Chemical Co.
  • Peripheral blood was taken from volunteers and 50 iu/ml heparin was added.
  • the blood was diluted 1 :6 with serum-free DMEM and incubated for 4 hours at 37°C in a water bath in the presence or absence of l ⁇ g/ml lipopolysaccharide (LPS) (E.col ⁇ ) and EGCG (20 ⁇ M).
  • LPS lipopolysaccharide
  • EGCG 20 ⁇ M
  • the blood was freeze-thawed thrice at -40°C and then centrifuged at 1000 rpm for 5 min to remove cell debris.
  • a TNF ⁇ ELISA was then performed on the supernatant following the manufacturers' instructions, either using a kit from R&D systems or from Diaclone Research. RESULTS
  • EGCG significantly inhibited rhTNF ⁇ -stimulated cartilage proteoglycan degradation in a bovine nasal cartilage explant model, but no significant effect was observed for the basal, rhILl ⁇ -, or Ret-stimulated release. Both ECG and EC significantly inhibited ILl ⁇ -stimulated degradation but not rhTNF ⁇ - or Ret- stimulated breakdown.
  • a dose-response curve was constructed (Fig. 2). Inhibition reached statistical significance at 2 ⁇ M (47% inhibition) and increased to 84% and 138% inhibition at 20 ⁇ M and 200 ⁇ M respectively. Where inhibition exceeded 100%) some of the basal breakdown as well as rhTNF ⁇ -stimulated breakdown is indicated.
  • EGCG at 200 ⁇ M was shown not to be toxic over a 5 day period by measurement of lactate levels in the conditioned media of bovine nasal cartilage explants stimulated with rhTNF ⁇ .
  • Explants cultured in DMEM alone produced 896 ⁇ g lactate/explant and in the presence of EGCG, this was 1040 ⁇ g lactate/explant.
  • When explants were cultured in the presence of rhTNF ⁇ a total of 1248 ⁇ g lactate/explant was produced, decreasing slightly to 896 ⁇ g when cultured in the presence of EGCG.
  • ECG (20 ⁇ M) produced significant inhibition of proteoglycan breakdown from human cartilage from osteoarthritic, rheumatoid and non-arthritic joints.
  • EGCG inhibited basal levels of proteoglycan loss from osteoarthritic cartilage (Table 2).
  • EGCG has been reported to inhibit TNF ⁇ synthesis in a human stomach cancer cell line KATO III (Okabe et al, 1999) and in BALB/3T3 cells (Suganuma et al, 1999).
  • KATO III human stomach cancer cell line
  • BALB/3T3 cells BALB/3T3 cells
  • Bovine nasal and articular cartilage explants were cultured for 5 days in serum-free DMEM in the presence or absence of rhIL-l ⁇ (0.3 nM nasal; 3nM articular). rhTNF ⁇ (3nM nasal; 6nM articular) or Ret (l ⁇ M) and in the presence or absence of the catechins EGCG, ECG, EC or EGC at a final concentration of 20 ⁇ M. Medium was changed on day 3. The degradation of cartilage proteoglycan was determined by measuring the sGAG released from the explants as a percentage of total sGAG using the DMB assay. The data are expressed as the mean percentage inhibition of stimulated or basal cartilage proteoglycan degradation ⁇ s.e.m.
  • Human osteoarthritic articular cartilage explants were biosynthetically labelled for 5 days in 5%(v/v) newborn calf serum (NCS)-containing DMEM using 35 SO 4 (5 ⁇ Ci/ml). The explants were washed for 2 days and then cultured for a further 9 days in the presence or absence of a combination of rhlLl ⁇ (3nM) and rhTNF ⁇ (6nM) and also in the presence or absence of the catechins EGCG or ECG at 20 ⁇ M. Medium was changed on day 3 and day 6.
  • the degradation of cartilage proteoglycan was determined by measuring the radiolabel released from the explants as a percentage of total radiolabel by quantifying the 35 S released into the culture medium and that retained in the tissue by use of a scintillation counter. The data are expressed as the mean percentage release ⁇ s.e.m. *p ⁇ 0.05, when the release of sGAG is compared between the groups cultured in the presence of the catechins to those cultured in their absence, as determined by the Mann Whitney U test for 2-tailed, non-parametric data. Table 3
  • Human non-rheumatoid articular cartilage was obtained from a patient suffering from Marfan's Syndrome at surgery, and cultured overnight in 5%(v/v) NCS-containing DMEM. Explants were individually transferred to a 96-well plate and cultured for 9 days in serum-free DMEM in the presence or absence of a combination of rhIL- 1 ⁇ (3nM) and rhTNF ⁇ (6nM) and also in the presence or absence of the catechins EGCG or ECG at 20 ⁇ M. Medium was changed at 3 and 6 days.
  • the degradation of the cartilage proteoglycan was determined by measuring sGAG released from the explants as a percentage of total sGAG using the DMB assay; ** p ⁇ 0.005 when comparing the proteoglycan released from the group cultured with the cytokine combination to the other groups, as determined using the 2-tailed Mann Whitney test for non-parametric data. Table 5
  • Human peripheral blood was diluted 1 :6 with serum-free DMEM and then incubated for 4 hours at 37°C in a water bath in the presence or absence of bacterial lipopolysaccharide (LPS) (l ⁇ g/ml) and EGCG (20 ⁇ M).
  • LPS bacterial lipopolysaccharide
  • EGCG EGCG (20 ⁇ M).

Abstract

L'invention porte sur l'utilisation de cathéchines dans le traitement de diverses formes de l'arthrite, et sur l'utilisation de combinaisons de catéchines et autres agents antiarthritiques ; sur des médicaments et des compositions destinés à être utilisés dans ce traitement et sur des procédés d'identification d'agents aux propriétés antiarthritiques.
EP00935346A 1999-06-07 2000-06-06 Traitement de l'arthrite Withdrawn EP1207862A2 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13769999P 1999-06-07 1999-06-07
US137699P 1999-06-07
GB0007321A GB0007321D0 (en) 2000-03-27 2000-03-27 Arthritis treatment
GB0007321 2000-03-27
PCT/GB2000/002048 WO2000074662A2 (fr) 1999-06-07 2000-06-06 Traitement de l'arthrite

Publications (1)

Publication Number Publication Date
EP1207862A2 true EP1207862A2 (fr) 2002-05-29

Family

ID=26243965

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00935346A Withdrawn EP1207862A2 (fr) 1999-06-07 2000-06-06 Traitement de l'arthrite

Country Status (4)

Country Link
EP (1) EP1207862A2 (fr)
JP (1) JP2003501381A (fr)
AU (1) AU5089400A (fr)
WO (1) WO2000074662A2 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002039956A2 (fr) 2000-11-15 2002-05-23 Rutgers, The State University Of New Jersey Extrait de the noir pour prevention de pathologies
WO2002069883A2 (fr) * 2001-02-06 2002-09-12 Universita Degli Studi Di Padova Procede pour inhiber l'elastase leucocytaire
JP2005521629A (ja) * 2001-06-25 2005-07-21 デピユイ・インターナシヨナル・リミテツド 関節炎の関節を治療するためのグリコサミノグリカンとヒアルロニダーゼ阻害剤を含んで成る組成物
JP2004535434A (ja) * 2001-06-25 2004-11-25 デピユイ 関節炎にかかった関節の処置のためのグリコサミノグリカン類のリポソームカプセル化
US7514469B2 (en) 2002-04-30 2009-04-07 Unigen Pharmaceuticals, Inc. Formulation of a mixture of Free-B-ring flavonoids and flavans as a therapeutic agent
US7108868B2 (en) 2002-03-22 2006-09-19 Unigen Pharmaceuticals, Inc. Isolation of a dual cox-2 and 5-lipoxygenase inhibitor from acacia
US7972632B2 (en) 2003-02-28 2011-07-05 Unigen Pharmaceuticals, Inc. Identification of Free-B-Ring flavonoids as potent COX-2 inhibitors
US8034387B2 (en) 2002-04-30 2011-10-11 Unigen, Inc. Formulation of a mixture of free-B-ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments
CA2521429A1 (fr) 2003-04-04 2004-10-21 Unigen Pharmaceuticals, Inc. Formulation destinee a inhiber la cyclooxygenase (cox) et la lipoxygenase (lox) utilisee dans les soins cutanes
JPWO2004091642A1 (ja) * 2003-04-11 2006-07-06 協和醗酵工業株式会社 関節炎の予防または治療剤
US7858080B2 (en) 2005-05-20 2010-12-28 Agency For Science, Technology And Research Aldehyde conjugated flavonoid preparations
WO2006124000A1 (fr) * 2005-05-20 2006-11-23 Agency For Science, Technology And Research Preparations de flavonoides conjugues a des aldehydes
BRPI0610180A2 (pt) * 2005-05-24 2012-09-25 Wellgen Inc métodos para prevenir, para tratar, e para tratar ou controlar uma condição associada à inflamação
DE102005029845B4 (de) * 2005-06-27 2017-03-23 Orgentec Diagnostika Gmbh Verfahren zur Diagnose von rheumatischen Erkrankungen
US20090286869A1 (en) * 2005-11-01 2009-11-19 Mars, Inc. Flavanols and B-Type Procyanidins and Inflammation
US8398611B2 (en) * 2010-12-28 2013-03-19 Depuy Mitek, Inc. Compositions and methods for treating joints
US8455436B2 (en) 2010-12-28 2013-06-04 Depuy Mitek, Llc Compositions and methods for treating joints
EP2996704B1 (fr) * 2013-05-14 2021-01-06 Mars, Incorporated Composition de soin des articulations
EP3041830B1 (fr) * 2013-09-03 2023-10-25 Agency For Science, Technology And Research Conjugués polymère-flavonoïde et hydrogels pour applications biomédicales
JP6242669B2 (ja) * 2013-11-27 2017-12-06 日本メナード化粧品株式会社 サルナシ抽出物を含有するヒアルロン酸生成促進剤
KR102102093B1 (ko) * 2014-05-09 2020-04-17 에이전시 포 사이언스, 테크놀로지 앤드 리서치 미셀 나노복합체
WO2015174934A1 (fr) * 2014-05-15 2015-11-19 Agency For Science, Technology And Research Conjugué polymere-flavonoïde et utilisations associées
US9682099B2 (en) 2015-01-20 2017-06-20 DePuy Synthes Products, Inc. Compositions and methods for treating joints
JP6742575B2 (ja) * 2015-07-02 2020-08-19 株式会社東洋新薬 関節機能改善組成物
JP2018100238A (ja) * 2016-12-21 2018-06-28 花王株式会社 歩行機能改善剤
WO2024003061A1 (fr) * 2022-06-30 2024-01-04 Lo.Li. Pharma S.R.L. Composition pour le traitement de l'infection par le papillomavirus humain (vph)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4268517A (en) * 1979-08-30 1981-05-19 Continental Pharma Pharmaceutical composition and therapeutical method for treating degenerative affections of the articular cartilage
BE886568A (fr) * 1980-12-09 1981-06-09 Continental Pharma Composition pharmaceutique pour le traitement des affections degeneratives du cartilage articulaire, et methode d'utilisation de celle-ci.
JPH07223941A (ja) * 1994-02-14 1995-08-22 Nippon Ham Kk 抗補体作用物質
IT1275905B1 (it) * 1995-03-14 1997-10-24 Indena Spa Frazioni polifenoliche di te', loro uso e formulazioni che le contengono
CA2175985A1 (fr) * 1995-05-10 1996-11-11 Yoichi Kiyosuke Composition pharmaceutique renfermant une substance empechant la production de hsp47
JP3718543B2 (ja) * 1995-06-28 2005-11-24 天野エンザイム株式会社 配糖体及び糖転移生成物の製造法
GB2306321A (en) * 1995-10-24 1997-05-07 Anne Child The use of (+)-catechin in the treatment or prophylaxis of connective tissue disorders
JPH09227374A (ja) * 1996-02-28 1997-09-02 Taiyo Kagaku Co Ltd ストレスタンパク質産生抑制組成物
JP4507027B2 (ja) * 1998-12-04 2010-07-21 明治乳業株式会社 Ｍｍｐ阻害剤
SE9900473D0 (sv) * 1999-02-12 1999-02-12 Karolinska Innovations Ab Inhibitor of endothelial cell proliferation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0074662A2 *

Also Published As

Publication number Publication date
AU5089400A (en) 2000-12-28
WO2000074662A3 (fr) 2002-03-14
JP2003501381A (ja) 2003-01-14
WO2000074662A2 (fr) 2000-12-14

Similar Documents

Publication Publication Date Title
EP1207862A2 (fr) Traitement de l'arthrite
JP2015120739A (ja) カンナビノイドの新用途
US20020077299A1 (en) Combinations of sesquiterpene lactones and ditepene triepoxide lactones for synergistic inhibition of cyclooxygenase-2
CA2451248A1 (fr) Composition comprenant des glycosaminoglycanes et des inhibiteurs d'hyaluronidase destinee au traitement d'articulations arthritiques
KR100728096B1 (ko) 관절성 질환 치료제
Yang et al. Protective effect of resveratrol on knee osteoarthritis and its molecular mechanisms: a recent review in preclinical and clinical trials
EP2282743A1 (fr) Sulfate de chondroïtine disaccharidique insaturé sulfaté dans la protection et la réparation de tissus conjonctifs
US8071137B2 (en) Method for treatment of cartilage disorders with centella extract
WO2020104833A1 (fr) Composition et procédés pour réguler la prolifération de chondrocytes et augmenter la production de matrice cartilagineuse
US20070154540A1 (en) Composition for treatment of osteoarthritis containing apigenin as chondroregenerative agent
Kwatra et al. Reviewing effects of rosehip, curcumin, piperine and chondroitin sulfate on collagen
WO2008139314A1 (fr) Compositions et procédés de traitement de troubles articulaires
Reginster et al. Non-steroidal, anti-inflammatory drug administration in the treatment of osteoarthritis
Busa et al. Vitamin D reduces pain and cartilage destruction in knee osteoarthritis animals through inhibiting the matrix metalloprotease (MMPs) expression
Elfadil et al. Protective role of curcumin, glucosamine and vitamin C on oxidative stress, biochemical and histopathological alterations induced by levofloxacin.
Gupta et al. Nutraceuticals in arthritis
WO2014031087A1 (fr) Formulations synergiques naturelles contenant des extraits d'andrographis paniculata pour soutenir l'inhibition de la dégradation des cartilages dans une maladie articulaire dégénérative
Medhi et al. Comparative clinical trial of paracetamol alone and vitamin C and E as an add on therapy in patients suffering from primary knee osteoarthritis.
JP4976031B2 (ja) ガラクツロン酸を有効成分とする軟骨生成促進剤
St-Pierre et al. Anti-Inflammatory Properties of Glucosamine Used in Combination with Plants Extracts on Adjuvant Arthritis Rat
EP4351589A1 (fr) Composition destinée à être utilisée dans la prévention et/ou le traitement de maladies ostéoarticulaires
EP2318014B1 (fr) Nouvelle composition pour le traitement de troubles auto-immuns
Komathi Therapeutic effect of Vitamin E in patients with primary osteoarthritis
Qu Articular cartilage proteoglycan biosynthesis and sulfation
Qu Articular cartilage proteoglycan biosynthesis and sulfation (Nivelruston proteoglykaanien biosynteesi ja sulfaatio)

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20011204

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

17Q First examination report despatched

Effective date: 20030618

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20031029